Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data
This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.
We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.
At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.
As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools.
We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
We connected with Jared Baeten, Gilead’s Vice President of HIV Clinical Development to discuss the top highlights from AIDS 2022, and ways the company is looking to help transform care and improve outcomes for people affected by HIV.
Pharma’s reputation may have soared amid the pandemic, but that came with a brighter spotlight on diversity, equity and inclusion issues. In recent years, pharma has been trying to incorporate DEI more deeply into its corporate psyche.
The goal of the hackathon was to identify innovative, digital solutions to help improve PrEP education, access and care services, particularly for the Black and Hispanic/Latinx communities in the Southern United States.
In the corporate partnership landscape, GenderCool is increasing awareness of trans issues through its reverse mentorship program, where a champion is paired with a company for eight weeks.
Read more to discover how Ashley has been able to broaden her impact on the HIV epidemic while working in an environment where she feels comfortable being her full, authentic self.
Listen to episode 2 of our Hepcast as we follow the journey of a young man living with HepatitisB. He’s joined by Arafat Bwambale from the Great Lakes Peace Centre in Uganda and Manal El Sayed from Ain Shams University in Egypt.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...